GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » PS Ratio

CBIO (Crescent Biopharma) PS Ratio : (As of Jul. 03, 2025)


View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Crescent Biopharma's share price is $15.89. Crescent Biopharma does not have enough years/quarters to calculate the Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024. Therefore GuruFocus does not calculate PS Ratio at this moment.

The historical rank and industry rank for Crescent Biopharma's PS Ratio or its related term are showing as below:

CBIO's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.325
* Ranked among companies with meaningful PS Ratio only.

Crescent Biopharma's Revenue per Sharefor the three months ended in Dec. 2024 was $0.00.

Back to Basics: PS Ratio


Crescent Biopharma PS Ratio Historical Data

The historical data trend for Crescent Biopharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescent Biopharma PS Ratio Chart

Crescent Biopharma Annual Data
Trend Dec24
PS Ratio
-

Crescent Biopharma Quarterly Data
Dec24
PS Ratio -

Competitive Comparison of Crescent Biopharma's PS Ratio

For the Biotechnology subindustry, Crescent Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescent Biopharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's PS Ratio falls into.


;
;

Crescent Biopharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Crescent Biopharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=15.89/
=

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Crescent Biopharma  (NAS:CBIO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Crescent Biopharma PS Ratio Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescent Biopharma Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.